Are the antiplatelet and profibrinolytic properties of selective serotonin-reuptake inhibitors relevant to their brain effects?

Thrombosis Research

Volumn 134, Issue 1, 2014, Pages 11-16

  Hoirisch Clapauch, Silvia ^a   Nardi, Antonio E ^b   Gris, Jean Christophe ^c   Brenner, Benjamin ^d  

^a MINISTÉRIO DA SAÚDE   (Brazil)

^b FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^c NÎMES UNIVERSITY HOSPITAL   (France)

^d TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

Antithrombotics; Selective serotonin reuptake inhibitors (SSRIs); Severe depression

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; PLASMIN; SEROTONIN; SEROTONIN UPTAKE INHIBITOR; TISSUE PLASMINOGEN ACTIVATOR; ANTIDEPRESSANT AGENT;

ANTICOAGULATION; BLOOD CLOTTING; BRAIN; CARDIOVASCULAR RISK; DRUG EFFECT; DRUG MECHANISM; ENDOTHELIUM; FIBRINOLYSIS; HUMAN; INFLAMMATION; MAJOR DEPRESSION; NEUROBIOLOGY; NEUROENDOCRINE SYSTEM; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; REVIEW; THROMBOCYTE; DRUG EFFECTS; THROMBOCYTE ACTIVATION;

ANTIDEPRESSIVE AGENTS; BLOOD PLATELETS; BRAIN; HUMANS; PLATELET ACTIVATION; SEROTONIN UPTAKE INHIBITORS;

EID: 84902550533     PISSN: 00493848     EISSN: 18792472     Source Type: Journal    
DOI: 10.1016/j.thromres.2014.02.028     Document Type: Review

References (72)

1. V.G. Manolopoulos, G. Ragia, and G. Alevizopoulos Pharmacokinetic interactions of selective serotonin reuptake inhibitors with other commonly prescribed drugs in the era of pharmacogenomics Drug Metabol Drug Interact 27 2012 19 31
2. D. Lam, D.A. Gorman, S. Patten, and T. Pringsheim The pharmacoepidemiology of selective serotonin reuptake inhibitors for children and adolescents in Canada from 2005 to 2009: a database analysis Paediatr Drugs 15 2013 319 327
3. J.C. Fournier, R.J. DeRubeis, S.D. Hollon, S. Dimidjian, J.D. Amsterdam, and R.C. Shelton et al. Antidepressant drug effects and depression severity: a patient-level meta-analysis JAMA 303 2010 47 53
4. T.K. Murphy, A. Segarra, E.A. Storch, and W.K. Goodman SSRI adverse events: how to monitor and manage Int Rev Psychiatry 20 2008 203 208
5. C. Kati, S. Karadas, M. Aslan, H. Gonullu, L. Duran, and H. Demir Serum paraoxonase and arylesterase activities and oxidative stress levels in patients with SSRI intoxication J Membr Biol 247 2014 17 21
6. D.G. Hackam, and M. Mrkobrada Selective serotonin reuptake inhibitors and brain hemorrhage: a meta-analysis Neurology 79 2012 1862 1865
7. K.L. Movig, M.W. Janssen, Malefijt J. de Waal, P.J. Kabel, H.G. Leufkens, and A.C. Egberts Relationship of serotonergic antidepressants and need for blood transfusion in orthopedic surgical patients Arch Intern Med 163 2003 2354 2358
8. L. Opatrny, J.A. Delaney, and S. Suissa Gastro-intestinal haemorrhage risks of selective serotonin receptor antagonist therapy: a new look Br J Clin Pharmacol 66 2008 76 81
9. C.B. Taylor, M.E. Youngblood, D. Catellier, R.C. Veith, R.M. Carney, and M.M. Burg et al. Effects of antidepressant medication on morbidity and mortality in depressed patients after myocardial infarction Arch Gen Psychiatry 62 2005 792 798
10. D.J. Kupfer, E. Frank, and M.L. Phillips Major depressive disorder: new clinical, neurobiological, and treatment perspectives Lancet 379 2012 1045 1055
11. P.B. Fitzgerald, A.R. Laird, J. Maller, and Z.J. Daskalakis A meta-analytic study of changes in brain activation in depression Hum Brain Mapp 29 2008 683 695
12. L. Zhou, J. Xiong, Y. Lim, Y. Ruan, C. Huang, and Y. Zhu et al. Upregulation of blood proBDNF and its receptors in major depression J Affect Disord 150 2013 776 784
13. L. Musazzi, A. Cattaneo, D. Tardito, A. Barbon, M. Gennarelli, and S. Barlati et al. Early raise of BDNF in hippocampus suggests induction of posttranscriptional mechanisms by antidepressants BMC Neurosci 10 2009 48
14. R.J. Tynan, J. Weidenhofer, M. Hinwood, M.J. Cairns, T.A. Day, and F.R. Walker A comparative examination of the anti-inflammatory effects of SSRI and SNRI antidepressants on LPS stimulated microglia Brain Behav Immun 26 2012 469 479
15. A. Serretti, M. Kato, D. De Ronchi, and T. Kinoshita Meta-analysis of serotonin transporter gene promoter polymorphism (5-HTTLPR) association with selective serotonin reuptake inhibitor efficacy in depressed patients Mol Psychiatry 12 2007 247 257
16. J. Licinio, C. Dong, and M.L. Wong Novel sequence variations in the brain-derived neurotrophic factor gene and association with major depression and antidepressant treatment response Arch Gen Psychiatry 66 2009 488 497
17. G. Jedlitschky, A. Greinacher, and H.K. Kroemer Transporters in human platelets: physiologic function and impact for pharmacotherapy Blood 119 2012 3394 3402
18. A.M. Carneiro, E.H. Cook, D.L. Murphy, and R.D. Blakely Interactions between integrin alphaIIbbeta3 and the serotonin transporter regulate serotonin transport and platelet aggregation in mice and humans J Clin Invest 118 2008 1544 1552
19. H. Kawano, H. Tsuji, H. Nishimura, S. Kimura, S. Yano, and N. Ukimura et al. Serotonin induces the expression of tissue factor and plasminogen activator inhibitor-1 in cultured rat aortic endothelial cells Blood 97 2001 1697 1702
20. F. Kilic Plasma serotonin level and the surface expression of platelet serotonin transporter Gordon Research Conference on Cell Biology of Megakaryocytes & Platelets. 2009, March 15-20, Galveston, TX, USA 2009
21. L.A. Erickson, M.H. Ginsberg, and D.J. Loskutoff Detection and partial characterization of an inhibitor of plasminogen activator in human platelets J Clin Invest 74 1984 1465 1472
22. H. Brogren, L. Karlsson, M. Andersson, L. Wang, D. Erlinge, and S. Jern Platelets synthesize large amounts of active plasminogen activator inhibitor 1 Blood 104 2004 3943 3948
23. S.J. Tsai The P11, tPA/plasminogen system and brain-derived neurotrophic factor: Implications for the pathogenesis of major depression and the therapeutic mechanism of antidepressants Med Hypotheses 68 2007 180 183
24. I. Lopez-Vilchez, M. Diaz-Ricart, J.G. White, G. Escolar, and A.M. Galan Serotonin enhances platelet procoagulant properties and their activation induced during platelet tissue factor uptake Cardiovasc Res 84 2009 309 316
25. A.M. Galan, I. Lopez-Vilchez, M. Diaz-Ricart, F. Navalon, E. Gomez, and C. Gasto et al. Serotonergic mechanisms enhance platelet-mediated thrombogenicity Thromb Haemost 102 2009 511 519
26. A. Srikiatkhachorn, C. Suwattanasophon, U. Ruangpattanatawee, and P. Phansuwan-Pujito Wolff Award. 5-HT2A receptor activation and nitric oxide synthesis: a possible mechanism determining migraine attacks Headache 42 2002 566 574
27. L. Qin, D. Zhao, J. Xu, X. Ren, E.F. Terwilliger, and S. Parangi et al. The vascular permeabilizing factors histamine and serotonin induce angiogenesis through TR3/Nur77 and subsequently truncate it through thrombospondin-1 Blood 121 2013 2154 2164
28. C. Dees, A. Akhmetshina, P. Zerr, N. Reich, K. Palumbo, and A. Horn et al. Platelet-derived serotonin links vascular disease and tissue fibrosis J Exp Med 208 2011 961 972
29. A.K. Stunes, J.E. Reseland, O. Hauso, M. Kidd, K. Tommeras, and H.L. Waldum et al. Adipocytes express a functional system for serotonin synthesis, reuptake and receptor activation Diabetes Obes Metab 13 2011 551 558
30. D.J. Walther, J.U. Peter, S. Winter, M. Holtje, N. Paulmann, and M. Grohmann et al. Serotonylation of small GTPases is a signal transduction pathway that triggers platelet alpha-granule release Cell 115 2003 851 862
31. N. Paulmann, M. Grohmann, J.P. Voigt, B. Bert, J. Vowinckel, and M. Bader et al. Intracellular serotonin modulates insulin secretion from pancreatic beta-cells by protein serotonylation PLoS Biol 7 2009 e1000229
32. A. Festa, R. D'Agostino Jr., L. Mykkanen, R.P. Tracy, D.J. Zaccaro, and C.N. Hales et al. Relative contribution of insulin and its precursors to fibrinogen and PAI-1 in a large population with different states of glucose tolerance. The Insulin Resistance Atherosclerosis Study (IRAS) Arterioscler Thromb Vasc Biol 19 1999 562 568
33. E.S. Brown, A.J. Rush, and B.S. McEwen Hippocampal remodeling and damage by corticosteroids: implications for mood disorders Neuropsychopharmacology 21 1999 474 484
34. E.J. Nestler, M. Barrot, R.J. DiLeone, A.J. Eisch, S.J. Gold, and L.M. Monteggia Neurobiology of depression Neuron 34 2002 13 25
35. A.L. Lussier, K. Lebedeva, E.Y. Fenton, A. Guskjolen, H.J. Caruncho, and L.E. Kalynchuk The progressive development of depression-like behavior in corticosterone-treated rats is paralleled by slowed granule cell maturation and decreased reelin expression in the adult dentate gyrus Neuropharmacology 71 2013 174 183
36. A. Mateus-Pinheiro, L. Pinto, J.M. Bessa, M. Morais, N.D. Alves, and S. Monteiro et al. Sustained remission from depressive-like behavior depends on hippocampal neurogenesis Transl Psychiatry 3 2013 e210
37. A. Surget, M. Saxe, S. Leman, Y. Ibarguen-Vargas, S. Chalon, and G. Griebel et al. Drug-dependent requirement of hippocampal neurogenesis in a model of depression and of antidepressant reversal Biol Psychiatry 64 2008 293 301
38. S. Tamura, H. Suzuki, Y. Hirowatari, M. Hatase, A. Nagasawa, and K. Matsuno et al. Release reaction of brain-derived neurotrophic factor (BDNF) through PAR1 activation and its two distinct pools in human platelets Thromb Res 128 2011 e55 e61
39. K. Martinowich, H. Manji, and B. Lu New insights into BDNF function in depression and anxiety Nat Neurosci 10 2007 1089 1093
40. A. Rozanski, J.A. Blumenthal, and J. Kaplan Impact of psychological factors on the pathogenesis of cardiovascular disease and implications for therapy Circulation 99 1999 2192 2217
41. B. Rudisch, and C.B. Nemeroff Epidemiology of comorbid coronary artery disease and depression Biol Psychiatry 54 2003 227 240
42. R. Rugulies Depression as a predictor for coronary heart disease a review and meta-analysis Am J Prev Med 23 2002 51 61
43. A. Nicholson, H. Kuper, and H. Hemingway Depression as an aetiologic and prognostic factor in coronary heart disease: a meta-analysis of 6362 events among 146 538 participants in 54 observational studies Eur Heart J 27 2006 2763 2774
44. D.E. Bush, R.C. Ziegelstein, M. Tayback, D. Richter, S. Stevens, and H. Zahalsky et al. Even minimal symptoms of depression increase mortality risk after acute myocardial infarction Am J Cardiol 88 2001 337 341
45. A. Pan, N. Keum, O.I. Okereke, Q. Sun, M. Kivimaki, and R.R. Rubin et al. Bidirectional association between depression and metabolic syndrome: a systematic review and meta-analysis of epidemiological studies Diabetes Care 35 2012 1171 1180
46. J.A. Gavard, P.J. Lustman, and R.E. Clouse Prevalence of depression in adults with diabetes An epidemiological evaluation Diabetes Care 16 1993 1167 1178
47. S.A. Everson-Rose, P.M. Meyer, L.H. Powell, D. Pandey, J.I. Torrens, and H.M. Kravitz et al. Depressive symptoms, insulin resistance, and risk of diabetes in women at midlife Diabetes Care 27 2004 2856 2862
48. Y.J. Hung, C.H. Hsieh, Y.J. Chen, D. Pei, S.W. Kuo, and D.C. Shen et al. Insulin sensitivity, proinflammatory markers and adiponectin in young males with different subtypes of depressive disorder Clin Endocrinol (Oxf) 67 2007 784 789
49. R. Visse, and H. Nagase Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry Circ Res 92 2003 827 839
50. M. Weiner, L. Warren, and J.G. Fiedorowicz Cardiovascular morbidity and mortality in bipolar disorder Ann Clin Psychiatry 23 2011 40 47
51. M. Leboyer, I. Soreca, J. Scott, M. Frye, C. Henry, and R. Tamouza et al. Can bipolar disorder be viewed as a multi-system inflammatory disease? J Affect Disord 141 2012 1 10
52. C.P. Chung, D. Schmidt, C.M. Stein, J.D. Morrow, and R.M. Salomon Increased oxidative stress in patients with depression and its relationship to treatment Psychiatry Res 206 2013 213 216
53. B.A. Abdel-Wahab, and R.H. Salama Venlafaxine protects against stress-induced oxidative DNA damage in hippocampus during antidepressant testing in mice Pharmacol Biochem Behav 100 2011 59 65
54. W. Chrapko, P. Jurasz, M.W. Radomski, S.L. Archer, S.C. Newman, and G. Baker et al. Alteration of decreased plasma NO metabolites and platelet NO synthase activity by paroxetine in depressed patients Neuropsychopharmacology 31 2006 1286 1293
55. R. Isaac, S. Boura-Halfon, D. Gurevitch, A. Shainskaya, Y. Levkovitz, and Y. Zick Selective serotonin reuptake inhibitors (SSRIs) inhibit insulin secretion and action in pancreatic beta cells J Biol Chem 288 2013 5682 5693
56. P.J. Goodnick Use of antidepressants in treatment of comorbid diabetes mellitus and depression as well as in diabetic neuropathy Ann Clin Psychiatry 13 2001 31 41
57. A. Thorell, M.F. Hirshman, J. Nygren, L. Jorfeldt, J.F. Wojtaszewski, and S.D. Dufresne et al. Exercise and insulin cause GLUT-4 translocation in human skeletal muscle Am J Physiol 277 1999 E733 E741
58. T.J. Raedler Inflammatory mechanisms in major depressive disorder Curr Opin Psychiatry 24 2011 519 525
59. J. Hannestad, N. DellaGioia, and M. Bloch The effect of antidepressant medication treatment on serum levels of inflammatory cytokines: a meta-analysis Neuropsychopharmacology 36 2011 2452 2459
60. F.R. Walker A critical review of the mechanism of action for the selective serotonin reuptake inhibitors: do these drugs possess anti-inflammatory properties and how relevant is this in the treatment of depression? Neuropharmacology 67 2013 304 317
61. P. Libby, and D.I. Simon Inflammation and thrombosis: the clot thickens Circulation 103 2001 1718 1720
62. Y. Bismuth-Evenzal, Y. Gonopolsky, D. Gurwitz, I. Iancu, A. Weizman, and M. Rehavi Decreased serotonin content and reduced agonist-induced aggregation in platelets of patients chronically medicated with SSRI drugs J Affect Disord 136 2012 99 103
63. F.J. de Abajo, D. Montero, L.A. Rodriguez, and M. Madurga Antidepressants and risk of upper gastrointestinal bleeding Basic Clin Pharmacol Toxicol 98 2006 304 310
64. B.O. Jeong, S.W. Kim, S.Y. Kim, J.M. Kim, I.S. Shin, and J.S. Yoon Use of serotonergic antidepressants and bleeding risk in patients undergoing surgery Psychosomatics 2013
65. D. Halperin, and G. Reber Influence of antidepressants on hemostasis Dialogues Clin Neurosci 9 2007 47 59
66. T. Cuisset, C. Frere, J. Quilici, F. Barbou, P.E. Morange, and T. Hovasse et al. High post-treatment platelet reactivity identified low-responders to dual antiplatelet therapy at increased risk of recurrent cardiovascular events after stenting for acute coronary syndrome J Thromb Haemost 4 2006 542 549
67. F. Geiser, R. Conrad, K. Imbierowicz, C. Meier, R. Liedtke, and D. Klingmuller et al. Coagulation activation and fibrinolysis impairment are reduced in patients with anxiety and depression when medicated with serotonergic antidepressants Psychiatry Clin Neurosci 65 2011 518 525
68. M. Claesson, L.S. Birgander, J.H. Jansson, B. Lindahl, G. Burell, and K. Asplund et al. Cognitive-behavioural stress management does not improve biological cardiovascular risk indicators in women with ischaemic heart disease: a randomized-controlled trial J Intern Med 260 2006 320 331
69. V.L. Serebruany, A.H. Glassman, A.I. Malinin, C.B. Nemeroff, D.L. Musselman, and L.T. van Zyl et al. Platelet/endothelial biomarkers in depressed patients treated with the selective serotonin reuptake inhibitor sertraline after acute coronary events: the Sertraline AntiDepressant Heart Attack Randomized Trial (SADHART) Platelet Substudy Circulation 108 2003 939 944
70. S.J. Tsai, C.J. Hong, Y.J. Liou, Y.W. Yu, and T.J. Chen Plasminogen activator inhibitor-1 gene is associated with major depression and antidepressant treatment response Pharmacogenet Genomics 18 2008 869 875
71. C. Knochel, V. Oertel-Knochel, L. O'Dwyer, D. Prvulovic, G. Alves, and B. Kollmann et al. Cognitive and behavioural effects of physical exercise in psychiatric patients Prog Neurobiol 96 2012 46 68
72. S.B. Vaisanen, S.E. Humphries, L.A. Luong, I. Penttila, C. Bouchard, and R. Rauramaa Regular exercise, plasminogen activator inhibitor-1 (PAI-1) activity and the 4G/5G promoter polymorphism in the PAI-1 gene Thromb Haemost 82 1999 1117 1120